With the advent of GLP-1 drugs, it was only a matter of time before co-hosts Brad Davidson and Gabriel Allen-Cummings dove into a discussion about this controversial drug class and the equally contentious disease of obesity. In this episode, they explore a range of topics—from the history of obesity and its recognition as a disease to how GLP-1s like Ozempic are influencing the conversation around the legitimacy and stigma of obesity beyond just Body Mass Index (BMI).
One of the most compelling ideas from this thought-provoking episode centers on control—how we perceive our own health and judge others, assuming people have more control over their health outcomes than they really do. This theme cuts to the heart of the obesity debate: are we excusing unhealthy habits, or are we acknowledging that the issue is far more complex than we originally thought?
Inspiration for this episode came from this op-ed in The New York Times: Are We Thinking About Obesity All Wrong?
Welcome to Breaking the Code! Behavioral science is a cornerstone of modern marketing practice, but much of what passes itself off as behavioral science is just bs. Good social science gives us the insights and roadmap we need to change behavior, but bad social science just muddies the water and tarnishes the social sciences. As behavior change is a core objective of marketing, getting behavioral science right is crucial. Listen in as hosts Brad Davidson, PhD and Sonika Garcia, MPH, Medical Anthropology Strategists at Havas Health, sound off on what is, and isn’t, good social science, from a variety of disciplines covering new topics every podcast.
Learn more on LinkedIn and Spotify.
The post Do GLP-1s Change the Meaning of “Obesity”? appeared first on PRINT Magazine.